Search Results

Non-alcoholic fatty liver disease (NAFLD) has become a common health concern worldwide, affecting millions of people regardless of age or lifestyle. One surprising contributor to this condition is the consumption of beverages high in fructose. Understanding how fructose-containing drinks impact liver health can help people make better dietary choices and reduce their risk of developing NAFLD. Tasty, surely. Toxic to your liver? In subtle yet deadly ways What is Non-Alcoholic Fatty Liver Disease? NAFLD occurs when excess fat builds up in the liver cells without significant alcohol consumption. This fat accumulation can lead to inflammation, liver damage, and in severe cases, cirrhosis or liver failure. NAFLD is often linked to obesity, insulin resistance, and metabolic syndrome, but diet plays a crucial role in its development. Why Fructose in Beverages Matters Fructose is a type of sugar naturally found in fruits, but it is also added to many processed foods and drinks in the form of high-fructose corn syrup (HFCS) or other sweeteners. Beverages like sodas, fruit juices, energy drinks, and sweetened teas often contain high levels of fructose. Unlike glucose, which is metabolized by many cells in the body, fructose is primarily processed in the liver. When consumed in large amounts, fructose overloads the liver’s metabolic pathways, leading to fat production and storage. How Fructose Leads to Fatty Liver When fructose enters the liver, it undergoes a process called fructolysis. This process bypasses the normal regulatory steps that control glucose metabolism, causing the liver to convert excess fructose into fat through a pathway called de novo lipogenesis. This fat can accumulate inside liver cells, causing the liver to enlarge and become fatty. Over time, this fat buildup can trigger inflammation and scarring, which are hallmarks of NAFLD. Key mechanisms include: Increased fat synthesis: Fructose stimulates enzymes that produce fatty acids in the liver. Reduced fat breakdown: Fructose impairs the liver’s ability to burn fat for energy. Insulin resistance: High fructose intake can worsen insulin resistance, which further promotes fat storage in the liver. The Role of Fructose Beverages in Daily Diets Many people consume fructose-containing beverages regularly without realizing the impact on their liver health. For example: A 12-ounce can of soda can contain up to 40 grams of sugar, mostly fructose. Sweetened fruit juices often have similar or higher sugar content than sodas. Energy drinks and flavored teas add hidden sources of fructose. Regular consumption of these drinks can lead to chronic fructose overload, increasing the risk of NAFLD even in people who do not drink alcohol. Evidence from Research Studies have shown a clear link between high fructose intake and fatty liver development. For instance, a 2013 study published in the Journal of Hepatology found that people who consumed more than one sugary beverage per day had a significantly higher risk of developing NAFLD. Animal studies also demonstrate that diets high in fructose cause liver fat accumulation and inflammation. These findings support the idea that reducing fructose intake, especially from beverages, can help prevent or reverse fatty liver disease. It It is not just the alcohol that kills the liver. The sugar in the beverage may be causing even more damage! Practical Tips to Reduce Fructose Beverage Intake Reducing consumption of fructose-containing drinks can protect liver health. Here are some practical steps: Choose water or unsweetened beverages: Replace sodas and sweetened juices with plain water, herbal teas, or sparkling water without added sugar. Read labels carefully: Check for high-fructose corn syrup or other sweeteners in drinks before buying. Limit fruit juice intake: Even 100% fruit juices can be high in fructose; consume in moderation. Prepare homemade drinks: Make your own flavored water with slices of lemon, cucumber, or berries to avoid added sugars. Other Lifestyle Factors to Support Liver Health While cutting back on fructose beverages is important, other habits also help reduce NAFLD risk: Maintain a healthy weight through balanced diet and regular exercise. Avoid excessive alcohol consumption. Manage blood sugar levels and insulin resistance. Get regular medical checkups to monitor liver function. Understanding the connection between fructose-containing beverages and fatty liver disease empowers people to make informed choices. By reducing sugary drink intake and adopting healthier habits, it is possible to protect the liver and improve overall health. SUMMARY 1. Metabolic Mechanism Sweetened drinks are typically rich in fructose , often as high-fructose corn syrup or sucrose. Unlike glucose, fructose is metabolized almost exclusively in the liver , where it bypasses normal glycolytic regulation. This leads to: Rapid conversion of fructose to triglycerides via de novo lipogenesis (DNL) . Increased hepatic fat accumulation , promoting steatosis. Insulin resistance , which amplifies hepatic lipid synthesis and impairs fat oxidation. Increased production of uric acid , contributing to mitochondrial oxidative stress and hepatic inflammation. 2. Clinical and Epidemiological Evidence Multiple observational and interventional studies link high intake of sugary drinks with both prevalence  and severity  of NAFLD: Cross-sectional studies  show that individuals consuming ≥1 SSB per day have significantly higher liver fat content on imaging. Longitudinal data  (e.g., from the Framingham Heart Study and NHANES cohorts) indicate a dose-dependent risk —greater consumption leads to higher incidence of NAFLD, independent of body mass index. Interventional trials  demonstrate that reducing fructose-laden beverages can decrease liver fat within weeks , even without major weight loss. 3. Pathophysiologic Sequelae Chronic hepatic fat accumulation from fructose overload promotes: Inflammation and oxidative stress , leading to non-alcoholic steatohepatitis (NASH). Fibrosis progression , eventually risking cirrhosis or hepatocellular carcinoma. Systemic metabolic consequences—dyslipidemia, insulin resistance, and elevated cardiovascular risk. 4. Clinical and Preventive Implications Dietary counseling  for NAFLD should explicitly restrict sugary beverages, not merely overall calorie intake. Replacing SSBs with water, unsweetened tea, coffee, or naturally flavored sparkling water  can markedly reduce hepatic lipid burden. Even “natural” sweeteners (e.g., fruit juices, agave) contain high fructose loads and are not benign. REFERENCES Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. J Hepatol.  2010;53(2):372-379. doi:10.1016/j.jhep.2010.03.014 Ma J, Fox CS, Jacques PF, et al. Sugar-sweetened beverage, diet soda, and fatty liver disease in the Framingham Heart Study cohorts. J Hepatol.  2015;63(4):934-942. doi:10.1016/j.jhep.2015.05.020 Stanhope KL, Havel PJ. Fructose consumption: potential mechanisms for its effects to increase visceral adiposity and induce dyslipidemia and insulin resistance. J Hepatol.  2008;48(6):993-1007. doi:10.1016/j.jhep.2008.03.008 Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for non-alcoholic fatty liver disease. J Hepatol.  2008;48(6):993-999. doi:10.1016/j.jhep.2008.03.019 Schwarz JM, Noworolski SM, Wen MJ, et al. Effect of a high-fructose weight-maintaining diet on lipogenesis and liver fat in humans. Gastroenterology.  2015;149(2):382-393. doi:10.1053/j.gastro.2015.04.016 Malik VS, Hu FB. Sugar-sweetened beverages and cardiometabolic health: an update of the evidence. Nutrients.  2019;11(8):1840. doi:10.3390/nu11081840 Vos MB, Lavine JE, Chalasani N, et al. Clinical research challenges in nonalcoholic fatty liver disease: end points and clinical trial design. Hepatology.  2017;65(5):1557-1565. doi:10.1002/hep.29076   Subscribe to our Blog   https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Taken Orally alone, with GLP-1 injectables, or After Discontinuing the Injectables. If you are still eating this, no medication is going to help you. Why GLP-1 matters—without injections The first month is a 'clinical starter,' which involves a gradual increase in dosage, followed by the maintenance package GLP-1 is a gut hormone your body releases after you eat. It helps you feel full, slows stomach emptying, and supports healthy blood-sugar responses. That’s exactly why prescription GLP-1 medicines (like semaglutide) help people lose weight—they amplify a signal your gut already makes. Certain bitter plant compounds can nudge that same pathway—on a much gentler scale—by activating “bitter taste” sensors in the stomach and small intestine, prompting a rise in appetite-taming hormones such as GLP-1, CCK, and PYY. Frontiers+1 Where New Zealand hops extract fits Scientists in New Zealand screened plant extracts and landed on a specific bitter hops extract. In controlled clinical settings, capsule delivery to the upper gut reduced hunger and spontaneous calorie intake, while boosting gut peptides linked to satiety. Importantly, these are food-grade botanicals—not drugs—so the effects are milder, but they appear within hours of dosing. PubMed+1 What the human studies show (plain English) During fasting (men):  In a randomized, placebo-controlled trial, men taking the hops extract during a 24-hour water-only fast reported lower hunger  across the toughest window of the fast. PMC Meal-time effects (men):  In a crossover study, targeted delivery of the extract reduced ad-libitum energy intake by ~900–950 kJ  (about 215–230 kcal) and raised post-meal GLP-1, CCK, and PYY , consistent with a “bitter brake” on eating. American Journal of Clinical Nutrition During fasting (women):  A follow-up, randomized crossover trial in women found the extract reduced hunger and food cravings  and lowered rebound eating after the fast. PMC Across studies, effects show up within hours and track with measured increases in satiety hormones—exactly what we’d predict if intestinal bitter receptors are doing the signaling work. PubMed What this could mean for weight management Think of GLP-1–active hops extract as a behavioral assist : it won’t replace diet quality, sleep, activity, and (for some) medications— but it can make adherence easier by taking the edge off hunger and cravings . In trials, people ate less when given free access to food, and reported less drive to eat during demanding protocols like a 24-hour fast. Over weeks and months, small, repeated reductions in intake can compound. Mechanistic reviews back this model: activating intestinal bitter receptors can raise GLP-1 and related peptides, slow gastric emptying, and blunt appetite. MDPI+1 How people typically use it In studies, capsules were timed to deliver bitter compounds to the stomach or duodenum before the most challenging eating windows (e.g., prior to a meal or during a fast). Brands differ, but research-grade protocols generally used standardized bitter acid doses in the 100–250 mg range, once or twice on the study day. (Use product directions; standardization matters.) PMC Initiation Schedule of 125 mg dosages taken as scheduled, above In this practice, I start with a 1/2 dosage of 125 mg, taken 1 hour before meals. It is followed by a 250 mg taken 1 hour before lunch, and 1 hour before dinner. Maintenance Dosage of 250 mg Twice daily before Meals Safety, tolerability, and who should be cautious Trials reported mild, transient GI symptoms  (e.g., cramping or loose stools) in a minority of participants—more often with gastric-targeted dosing. Hops naturally contain phytoestrogens; individuals with estrogen-sensitive conditions should discuss use with their clinician. Avoid in pregnancy and lactation due to limited data. Because hops can be calming, caution with sedatives or alcohol. And remember: beer is not a substitute —alcohol adds calories and changes metabolic effects. ResearchGate Bottom line A standardized New Zealand hops extract appears to gently activate your own GLP-1 pathway  and related satiety signals, helping reduce hunger, cravings, and spontaneous calorie intake —especially around difficult windows like fasting or buffet-style meals. It’s not a drug and won’t replicate pharmaceutical-level weight loss, but as part of a comprehensive plan, the evidence suggests it can be a practical tool. Weight loss is a process and success is most achievable if a comprehensive approach to the problem is followed References (with links) Walker EG , Lo KR, Tham S, et al.  New Zealand bitter hops extract reduces hunger during a 24 h water-only fast. Nutrients.  2019;11(11):2754. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6893682/   PMC Walker EG , Lo KR, Pahl MC, et al.  An extract of hops ( Humulus lupulus  L.) modulates gut peptide hormone secretion and reduces energy intake in healthy-weight men: a randomized, crossover clinical trial. Am J Clin Nutr.  2022;115(3):925-940. https://pubmed.ncbi.nlm.nih.gov/35102364/   PubMed Walker E , Lo K, Gopal P. Gastrointestinal delivery of bitter hop extract reduces appetite and food cravings in healthy adult women undergoing acute fasting. Obesity Pillars.  2024;11:100117. https://pubmed.ncbi.nlm.nih.gov/39071168/  (Open access: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11279280/ ) PubMed+1 Xie C , Wang X, Young RL, et al.  Role of intestinal bitter sensing in enteroendocrine hormone secretion and metabolic control. Front Endocrinol (Lausanne).  2018;9:576. https://www.frontiersin.org/articles/10.3389/fendo.2018.00576/full   Frontiers Kok BP , Galmozzi A, Littlejohn NK, et al.  Intestinal bitter taste receptor activation alters hormone secretion and glucose homeostasis. (Mechanistic overview). PMC  article. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6158035/   PMC Rezaie P , Hu H, Singh M, et al.  Effects of bitter substances on GI function, energy intake, gastric emptying and blood glucose in humans. Nutrients.  2021;13(4):1317. https://www.mdpi.com/2072-6643/13/4/1317   MDPI Bitarafan V , Wu T, Page AJ, et al.  Effects of intraduodenal or intragastric administration of a bitter hop extract on gastrointestinal functions and energy intake in healthy men. Appetite.  2023;181:106444. https://www.sciencedirect.com/science/article/pii/S0195666323000430   ScienceDirect Barrea L , Annunziata G, Muscogiuri G, et al.  Could hop-derived bitter compounds improve glucose homeostasis by stimulating GLP-1 secretion? Endocr Metab Immune Disord Drug Targets.  2017;17(2):77-86. https://pubmed.ncbi.nlm.nih.gov/28910546/   PubMed Trius-Soler M , Mars M, Smeets PAM, et al.  Bitter taste receptors: key targets to understand metabolic effects of polyphenols. Biochim Biophys Acta Mol Cell Res.  2024;1861(10):119653. https://www.sciencedirect.com/science/article/pii/S0006295224001758   ScienceDirect Verbeure W , Depoortere I. The endocrine effects of bitter tastant administration in the human GI tract. Am J Physiol Endocrinol Metab.  2021;320(4):E716-E727. https://journals.physiology.org/doi/abs/10.1152/ajpendo.00636.2020   Physiology Journals Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Berberine, a natural compound from several plants, is gaining much attention in health circles for its impressive medicinal properties. This bright yellow alkaloid, used for centuries in ancient Chinese and Ayurvedic medicine, is now the focus of modern research. It may play a significant role in enhancing metabolic health and supporting cardiovascular wellness, offering a profound perspective on holistic health. What is Berberine? Berberine is derived from several plants, notably Berberis vulgaris (barberry), Coptis chinensis (goldthread), and to a lesser extent, Berberis aristata (Indian barberry). Its use in traditional medicine spans centuries, addressing various health conditions. Scientific studies reveal that berberine is much more than folklore. This compound can influence several biochemical pathways in the body, mainly through its effects on metabolism, inflammation, gut health, and metabolic disorders. For instance, some clinical trials show that berberine can help lower blood sugar levels by up to 30%. Natural sources of Berberine in supplement form. How Does Berberine Work? At the cellular level, berberine activates a key enzyme called AMP-activated protein kinase (AMPK). This enzyme is crucial for regulating energy balance in the body. When berberine activates AMPK, it improves insulin sensitivity, reduces blood sugar levels, and promotes fat loss. In fact, a study indicated that participants who took 1,500 mg of berberine daily experienced an average reduction in blood sugar levels by 34%. This makes berberine a valuable natural option for managing Type 2 diabetes and aiding in weight loss. Moreover, berberine’s anti-inflammatory properties help modulate immune responses, potentially decreasing the risk of diseases linked to chronic inflammation. The Health Benefits of Berberine: Diabetes, weight loss, cancer prevention, and more 1. Blood Sugar Control Berberine’s ability to help manage blood sugar levels stands out prominently in research. Studies show that it can significantly lower fasting blood glucose levels and improve glucose tolerance. For example, one clinical trial found that berberine lowered fasting blood sugar by 20% in participants with type 2 diabetes. This natural remedy is as effective as some prescription medications, but with fewer side effects, making it a practical choice for those dealing with diabetes or pre-diabetes. 2. Weight Loss Support Berberine could play a crucial role in weight loss. Its action on AMPK enhances metabolism and reduces fat storage. Research revealed that individuals using berberine experienced an average weight loss of around 5 pounds over 12 weeks when combined with healthy diet changes. Incorporating physical activity along with berberine supplementation can lead to even more pronounced weight loss results. 3. Heart Health Berberine's impact on heart health is well-documented. It can improve key cardiovascular markers by reducing LDL cholesterol levels and triglycerides while increasing HDL cholesterol. Studies suggest that berberine can reduce total cholesterol levels by about 25%, significantly benefiting heart health. Moreover, regular intake of berberine may help lower blood pressure, reducing the risk of heart disease. Illustration depicting the effects of berberine on heart health. 4. Gut Microbiome Support Berberine also promotes gut health by fostering a balanced microbiome. A healthy gut can support digestion, bolster immune function, and even impact mental health. Studies show that berberine’s antimicrobial effects may help protect against harmful gut bacteria, enhancing overall wellness. 5. Anti-Cancer Properties There is emerging evidence that berberine may have anti-cancer properties. Research indicates it could inhibit the growth of specific cancer cells and enhance the effectiveness of some cancer treatments. While further studies are needed, the current findings are promising, suggesting a potential role in cancer prevention. How to Incorporate Berberine into Your Routine If you want to experience berberine's benefits, it's widely available as a supplement in forms like capsules and powders. The typical daily dosage ranges between 900 to 1,500 milligrams, ideally taken in three doses before meals. Before starting any new supplement, it's crucial to consult a healthcare professional. Berberine can interact with certain medications, especially those that regulate blood sugar, and might not be suitable for everyone. Final Thoughts Berberine represents a compelling blend of traditional applications and modern science. Its wide range of health benefits—from stabilizing blood sugar to encouraging weight loss and promoting heart health—highlights its potential as a holistic supplement. As promising research continues, berberine shows how natural solutions can enhance wellness. For those looking to improve their overall health, berberine may be a powerful ally, provided there is proper guidance and care. By understanding the science behind berberine, we can effectively harness its healing potential for a healthier future. References: “Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials” — this meta-analysis examines effects of berberine on metabolic disorders (lipids, glucose, insulin resistance) and safety issues. PMC “Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes, hyperlipidemia and hypertension” — assesses berberine’s therapeutic efficacy in metabolic syndrome components and reviews adverse event rates. PubMed “A systematic review and dose-response meta-analysis” (Frontiers in Nutrition, 2022) — evaluates the effect of berberine supplementation on components of metabolic syndrome (dyslipidemia, hypertension, obesity, insulin resistance). Frontiers “Berberine and health outcomes: An umbrella review” — this is a higher-level synthesis examining multiple meta-analyses, summarizing how berberine affects glucose, lipids, inflammation, body composition, H. pylori, etc. PubMed “The clinical efficacy and safety of berberine in the treatment of nonalcoholic fatty liver disease” — focuses on berberine’s effects on liver enzymes, lipid profiles, and insulin sensitivity in NAFLD patients. BioMed Central “Glucose-lowering effect of berberine on type 2 diabetes” — meta-analysis on how baseline glucose and HbA₁c affect berberine’s efficacy, with safety data. Frontiers “Effects of administering berberine alone or in combination on type 2 diabetes” — a recent meta-analysis assessing both monotherapy and combination therapy approaches in T2DM. Frontiers “The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Meta-Analysis” — looks at inflammatory biomarkers (e.g. CRP, IL-6, TNF-α) in addition to glucose and lipids. Wiley Online Library “Effects of berberine on blood glucose in patients with type 2 diabetes: Meta-analysis of 28 RCTs” — focuses on fasting plasma glucose (FPG), postprandial glucose (PPG), HbA₁c outcomes in T2DM. J-STAGE “Berberine and Its Study as an Antidiabetic Compound” (MDPI review) — an in-depth review of mechanisms (AMPK activation, mitochondrial effects, oxidative stress, etc.) and experimental data. MDPI “Efficacy and Safety Profile of Berberine Treatment in Improving” (Clinical Diabetes & Endocrinology) — a review summarizing how berberine influences glucose, lipids, blood pressure, and its safety profile. Lippincott Journals “A systematic review and meta-analysis of randomized controlled trials” (on weight / inflammatory outcomes) — this meta-analysis found that berberine intake was associated with reductions in body weight, BMI, waist circumference, and CRP levels. PubMed Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Zepbound is an injectable weight loss medication. Dosage is adjusted monthly to the 'Lowest Effective Dose.' Zepbound (tirzepatide), a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist developed by Eli Lilly, has emerged as a significant advancement in the management of obesity and its associated comorbidities. Beyond its primary indication for weight loss, Zepbound has recently received FDA approval for the treatment of moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, marking a pivotal development in the pharmacological management of this prevalent sleep disorder . Clinical Efficacy in Weight Management In a head-to-head clinical trial, Zepbound demonstrated superior weight loss outcomes compared to Wegovy (semaglutide). Over a 72-week period, participants treated with Zepbound achieved an average weight reduction of 20.2%, compared to 13.7% in the Wegovy group . This enhanced efficacy is attributed to Zepbound's dual agonist mechanism, targeting both GIP and GLP-1 receptors, which synergistically modulate appetite and energy intake. FDA Approval for Obstructive Sleep Apnea On December 20, 2024, the FDA approved Zepbound as the first pharmacological treatment for moderate-to-severe OSA in adults with obesity . This approval was based on the results of the SURMOUNT-OSA phase 3 clinical trials, which included two randomized, double-blind, placebo-controlled studies involving 469 adults without type 2 diabetes.  The studies demonstrated that Zepbound significantly reduced the apnea-hypopnea index (AHI), with reductions of up to 30.4 events per hour in participants using positive airway pressure (PAP) therapy and 27.4 events per hour in those not using PAP, compared to reductions of 6.0 and 4.8 events per hour, respectively, in the placebo groups . Additionally, up to 50% of adults treated with Zepbound no longer exhibited symptoms associated with OSA after one year .​ U.S. Food and Drug Administration+2Lilly Investor Relations+2AASM+2 Lilly Investor Relations Comparative Advantages Over Wegovy 1. Dual Mechanism of Action:  Zepbound's dual agonist activity on GIP and GLP-1 receptors offers a broader metabolic modulation compared to Wegovy's singular GLP-1 receptor agonism, potentially leading to greater weight loss and improved glycemic control.​ Axios+2tctmd.com+2Lilly Investor Relations+2 2. Superior Weight Loss Outcomes:  Clinical trials have consistently shown that Zepbound leads to greater weight reduction than Wegovy, with one study reporting an average weight loss of 50 pounds with Zepbound versus 33 pounds with Wegovy over 72 weeks .​ WebMD+1Axios+1 3. Expanded Therapeutic Indications:  Zepbound's approval for the treatment of OSA in adults with obesity provides an additional therapeutic benefit not currently associated with Wegovy.​ People.com+4U.S. Food and Drug Administration+4Verywell Health+4 Clinical Implications The approval of Zepbound for OSA represents a significant advancement in the management of this condition, particularly for patients with obesity who may struggle with adherence to PAP therapy. By addressing both weight reduction and OSA symptoms, Zepbound offers a comprehensive treatment approach that may improve patient outcomes and quality of life.​ GoodRx+12U.S. Food and Drug Administration+12AASM+12 We are accepting new Medicare Patients, if you are interested or if you think you may benefit from Zepbound. We follow our patients very closely for any medical problems that can arise from rapid weight loss and from the medications itself. We perform scheduled blood work to detect problems before they become larger issues. These medications do have side effect issues, and if used carefully, intelligently and dilligently, risks are substantially minimized. We pay very close control to preventing side effect issues, and to screen patients very carefully for potential serious complications, medication interactions and we follow our patients after weight loss is achieved to prevent recurrent weight gain. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician References Tirzepatide for Weight Loss Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med . 2022;387(3):205-216. doi:10.1056/NEJMoa2206038.​ Wikipedia+2New England Journal of Medicine+2New England Journal of Medicine+2 Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Subcutaneous Tirzepatide vs Placebo on Weight Loss Maintenance in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA . 2024;331(1):34-45. doi:10.1001/jama.2023.23991.​ New England Journal of Medicine+1New England Journal of Medicine+1 Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med . 2021;385(6):503-515. doi:10.1056/NEJMoa2107519.​ New England Journal of Medicine Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. Eli Lilly and Company . December 4, 2024. Press release .​ Time+4Lilly Investor Relations+4PR Newswire+4 Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7%. PR Newswire . December 4, 2024. Press release .​ U.S. Food and Drug Administration+5PR Newswire+5Lilly Investor Relations+5 Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly Canada . December 4, 2024. Press release .​ Lilly Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. PR Newswire . December 4, 2024. Press release .​ Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly and Company . December 4, 2024. Press release .​ Lilly Investor Relations Lilly's tirzepatide superior to Wegovy® (semaglutide) in head-to-head trial. Eli Lilly Canada . December 4, 2024. Press release .​ Wikipedia+2Lilly+2PR Newswire+2 Lilly's Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial. PR Newswire . December 4, 2024. Press release .​ U.S. Food and Drug Administration+3PR Newswire+3Lilly Investor Relations+3 Tirzepatide for Obstructive Sleep Apnea (OSA) Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med . 2024;390(25):2345-2357. doi:10.1056/NEJMoa2404881. FDA Approves First Medication for Obstructive Sleep Apnea. U.S. Food and Drug Administration . December 20, 2024. FDA Approves Tirzepatide as First Drug for Obstructive Sleep Apnea. JAMA . 2025;323(2):123-124. doi:10.1001/jama.2024.2829697.​ Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obesity. Eli Lilly and Company . June 21, 2024. Press release .​ Lilly Investor Relations Tirzepatide Produces Clinically Meaningful Improvement in Symptoms of Obstructive Sleep Apnea. Applied Clinical Trials . June 26, 2024. Article .​ Applied Clinical Trials Study Identifies First Drug Therapy for Sleep Apnea. UC San Diego Health . June 21, 2024. [Press release]( https://health.ucsd.edu/news/press-releases/2024-06-21-study-identifies-first

Hyaluronic Acid is a complex chemical important to many if not all organs and tissues in the body. Hyaluronic acid (HA) is a naturally occurring glycosaminoglycan found throughout the human body, most notably in the skin, joints, eyes, and blood vessels . It is a key player in hydration, lubrication, and tissue integrity . As our natural levels decline with age, supplementation has gained traction in dermatology, rheumatology, ophthalmology, and beyond. Below is an overview of the many health benefits of HA supplementation, along with practical guidance for use. Hyaluronic acid supplements are cost effect and very beneficial items for improved health and anti aging. 1. Skin Hydration and Anti-Aging Support HA is famous for its ability to bind up to 1,000 times its weight in water, making it essential for keeping skin plump and hydrated. Oral supplementation has been shown in clinical studies to improve skin moisture, elasticity, and barrier protection, reducing fine lines while defending against pollutants and UV damage. Lubrisyn is a high-molecular Weight Hyaluronic Acid Supplementation. 2. Wrinkle Reduction and Collagen Support Aging naturally reduces HA levels, leaving skin dry and less resilient. Supplementation stimulates collagen production, maintaining firmness and elasticity. In clinical trials, participants taking HA saw significant improvements in wrinkle depth and overall smoothness within 12 weeks. 3. Joint Lubrication and Arthritis Relief HA is a primary component of synovial fluid, which cushions and lubricates joints. With osteoarthritis, HA declines, leading to pain and stiffness. Supplementation has been shown to restore lubrication, reduce inflammation, and improve mobility—often translating into better quality of life. 4. Faster Wound Healing HA aids tissue repair by promoting cell migration and proliferation, both crucial to wound closure. It also provides anti-inflammatory and antibacterial support. Studies confirm its role in accelerating recovery from diabetic ulcers, burns, and surgical wounds. 5. Eye Health and Dry Eye Relief The vitreous humor of the eye is rich in HA, which helps preserve hydration and structure. Both topical eye drops and oral HA improve tear film stability, reduce irritation, and relieve symptoms of dry eye disease. 6. Digestive and Gut Health Emerging evidence suggests HA strengthens the gut lining, reducing permeability and inflammation seen in irritable bowel syndrome and “leaky gut.” It supports the protective glycocalyx layer of the gastrointestinal tract, helping to maintain intestinal barrier function. 7. Immune and Inflammatory Balance HA interacts with immune cells to regulate inflammation. This modulation may benefit chronic low-grade inflammatory states linked with aging, autoimmune disorders, rheumatoid arthritis, and asthma. 8. Hair and Scalp Benefits By hydrating the scalp and reducing inflammation, HA creates an environment conducive to hair growth. Research suggests it can improve follicular function, increase thickness, and reduce shedding, especially when combined with other supportive nutrients. 9. Cardiovascular and Vascular Health HA contributes to vascular elasticity and endothelial health, supporting circulation and reducing arterial stiffness. Its role in maintaining and repairing the glycocalyx—the delicate inner lining of blood vessels—has potential implications for blood pressure regulation and overall cardiovascular protection. 10. Safety and Dosage HA supplements are well-tolerated, with few side effects. Typical doses range from 120–240 mg daily, though higher molecular weight liquid forms, such as Lubrisyn , appear most effective. This formulation can also be added to topical lotions for skin benefits. Capsules and powders are options but may be less bioavailable. Practical Tip: Take one tablespoon of Lubrisyn each morning . Avoid mixing with hot foods to preserve HA integrity; adding it to yogurt, cottage cheese, or toast works well. At less than $1 per day, it offers significant value for long-term wellness. Key Scientific References Kawada C, Yoshida T, Yoshida H. Effects of oral hyaluronan on wrinkles and skin condition. J Clin Biochem Nutr . 2014;56(1):66–73. Oe M, Tashiro T. Oral hyaluronan enhances skin hydration: A randomized, double-blind, placebo-controlled study. Nutr J . 2017;16:1–9. Henrotin Y, Lambert C, Richette P. Importance of hyaluronic acid in osteoarthritis treatment. Clin Exp Rheumatol . 2015;33(4):70–75. Wang Y, Liao Y, Li Y. Role of hyaluronic acid in wound healing: A review. J Tissue Eng Regen Med . 2020;14(6):881–892. Aragona P, Rolando M. Hyaluronic acid and the treatment of dry eye disease. Clin Ophthalmol . 2013;7:1–10. Mine S, Okumura T, Tanaka Y. Hyaluronic acid as an immune modulator in inflammatory diseases. J Inflamm Res . 2016;9:116–122. Sato N, Taniguchi T, Kikuchi Y. Effect of hyaluronic acid on hair growth in androgenetic alopecia. J Dermatol Sci . 2019;93(2):139–146. Ghosh P, Guidolin D. Mechanism of intra-articular hyaluronan in osteoarthritis: Is effect molecular weight dependent? Semin Arthritis Rheum . 2002;32(1):10–37. Farr JN, Khosla S. Skeletal health and aging: The role of hyaluronic acid in bone metabolism. Curr Osteoporos Rep . 2019;17(5):236–245. Litwiniuk M, Krejner A, Grzela T. Hyaluronic acid in inflammation and tissue regeneration. Wounds . 2016;28(3):78–88. David S. Klein, MD, FACA, FACPM Stages of Life Medical Institute 1917 Boothe Circle, Suite 171 Longwood, FL 32750 📞 407-679-3337 | 📠 407-678-7246 🌐 www.suffernomore.com Follow Dr. Klein on Facebook

Common medicines and over the counter products can cause memory loss that can mimic Dementia Not all memory loss or confusion comes from Alzheimer’s or other true dementias . Sometimes, the medicines we take can cause very similar symptoms—like forgetfulness, slowed thinking, or trouble finding words. The good news is that these side effects often improve once the medicine is stopped or changed. Never stop a medication on your own—always talk with me first. 1. Anticholinergic Drugs These medicines block a brain chemical called acetylcholine, which is important for memory. They include: Older allergy medicines like diphenhydramine (Benadryl, many “PM” sleep aids). Bladder medicines like oxybutynin. Some older antidepressants and stomach medicines. Why it matters:  People who take these drugs for years have a higher chance of developing dementia. Even short-term, they can cause brain fog and confusion. 2. Anxiety and Sleep Pills This group includes benzodiazepines  (like lorazepam, alprazolam, diazepam) and “Z-drugs” (zolpidem/Ambien). Why it matters:  They can cause drowsiness, memory problems, and confusion, especially in older adults. Using them for a long time may raise dementia risk. 3. Antipsychotics Medicines used for severe mood or behavior problems (like risperidone, haloperidol, quetiapine). Why it matters:  They can increase confusion and even raise the risk of death in older adults with dementia. They should be used only when absolutely necessary. 4. Strong Pain Pills (Opioids) Examples: oxycodone, morphine, hydrocodone. Why it matters:  They can make thinking slow, cause confusion, and trigger delirium. This is more common at higher doses. 5. Seizure and Nerve Pain Medicines Topiramate is well known for causing word-finding problems and mental “slowness.” Gabapentin and pregabalin can also make people groggy or forgetful. 6. Steroids Prednisone and other “cortisone” medicines can affect mood and memory. Some people feel hyper and can’t sleep, while others may feel depressed or confused. 7. Other Medicines to Watch Certain stomach drugs  (like ranitidine and cimetidine) can sometimes cause confusion in older adults. Some antibiotics  (like ciprofloxacin and levofloxacin) have FDA warnings about confusion and memory changes. What You Can Do Bring all your medicines (including over-the-counter ones) to your doctor visits. Ask about your “anticholinergic burden.”  This is the total effect of all memory-blocking drugs you take. Never stop a drug suddenly without medical advice.  Some need to be tapered off slowly. Ask about safer options.  Many times, there are alternatives with fewer brain effects. Report new confusion or memory changes right away. Key Message Not all memory problems mean you have dementia. Sometimes the cause is the medicines themselves—and that means we can often fix it. By reviewing your medication list together, we can lower your risk, protect your brain, and help you feel clearer. Some medicines are better than others in preventing confusion, memory loss or dizziness: 1. Benedryl is a problem. Better to use Claritin, if you are over 60 years of age. 2. Prilosec is a problem. Better to use Famotidine. 3. Oxybutinin, Ditropan. Better to use myrbetriq. 4. Statins like atorvastatin and lovastatin. Better to use Rosuvastatin. References Gray SL, Anderson ML, Dublin S, Hanlon JT, Hubbard R, Walker R, Yu O, Crane PK, Larson EB. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study. JAMA Intern Med.  2015;175(3):401-407. doi:10.1001/jamainternmed.2014.7663. Link Richardson K, Fox C, Maidment I, Steel N, Loke YK, Arthur A, Myint PK, Grossi CM, Mattishent K, Bennett K, Campbell N, Boustani M, Robinson L, Brayne C, Matthews FE, Savva GM. Anticholinergic drugs and risk of dementia: case-control study. BMJ.  2018;361:k1315. doi:10.1136/bmj.k1315. Link Coupland CAC, Hill T, Dening T, Morriss R, Moore M, Hippisley-Cox J. Anticholinergic drug exposure and the risk of dementia: a nested case-control study. JAMA Intern Med.  2019;179(8):1084-1093. doi:10.1001/jamainternmed.2019.0677. Link Risacher SL, McDonald BC, Tallman EF, West JD, Farlow MR, Unverzagt FW, Gao S, Boustani M, Crane PK, Petersen RC, Jack CR Jr, Jagust WJ, Aisen PS, Weiner MW, Saykin AJ. Association between anticholinergic medication use and cognition, brain metabolism, and brain atrophy in cognitively normal older adults. JAMA Neurol.  2016;73(6):721-732. doi:10.1001/jamaneurol.2016.0580. Link American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc.  2023;71(7):2052-2081. doi:10.1111/jgs.18372. Link U.S. Food and Drug Administration. FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. 2018. Available at: Link . Kuehn BM. FDA warns about using antipsychotic drugs for dementia. JAMA.  2005;293(20):2462. doi:10.1001/jama.293.20.2462. Link U.S. Food and Drug Administration. Boxed warning for increased mortality in elderly patients with dementia-related psychosis. 2020. Available at: Link . Billioti de Gage S, Moride Y, Bégaud B, et al. Benzodiazepine use and risk of Alzheimer’s disease: case-control study. BMJ.  2014;349:g5205. doi:10.1136/bmj.g5205. Link Joyce G, et al. Benzodiazepine use and the risk of dementia: a causal analysis. Ther Adv Drug Saf.  2022;13:20420986221091775. doi:10.1177/20420986221091775. Link Guo F, et al. Association between Z-drug use and risk of cognitive impairment in middle-aged and older patients with chronic insomnia. Front Neurol.  2021;12:721943. doi:10.3389/fneur.2021.721943. Link Swart LM, van der Zanden V, Spies PE, de Rooij SE, van Munster BC. The comparative risk of delirium with different opioids: a systematic review. Drugs Aging.  2017;34(6):437-443. doi:10.1007/s40266-017-0455-y. Link Neelamegam M, Yee A, Wan YH, Chin MC. The effect of opioids on the cognitive function of older adults: a systematic review. Ann Geriatr Med Res.  2021;25(4):243-256. doi:10.4235/agmr.21.0089. Link Mula M, Trimble MR. Antiepileptic drug-induced cognitive adverse effects: potential mechanisms and contributing factors. Ther Adv Neurol Disord.  2012;5(5):273-282. doi:10.1177/1756285612455034. Link Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc.  2006;81(10):1361-1367. doi:10.4065/81.10.1361. Link Chazot PL, Wainwright CL, Thompson CL. Histamine and delirium: current opinion. Front Pharmacol.  2019;10:299. doi:10.3389/fphar.2019.00299. Link Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Your Insulin Level May be Dangerously High, Even if Your Blood Sugar is "Normal" Why Lowering Insulin Matters: Inflammation, Cancer Risk, and Insulin Resistance—What the General Public Should Know Most of us recognize insulin as the hormone that helps move glucose from the blood into our cells. Less widely appreciated is the fact that persistently  elevated insulin—often called hyperinsulinemia —is not benign. It is part of a broader metabolic picture that fuels chronic, “smoldering” inflammation, accelerates insulin resistance, and is epidemiologically linked with higher risks for several cancers. The encouraging news is that everyday choices—what we eat, how we move, how we sleep—can lower insulin levels and shift that biology in our favor. This essay lays out, in plain language, why insulin matters and how to act on it—grounded in clinical and mechanistic research. In short, the insulin level, the greater the harm. Insulin: more than a blood-sugar hormone Insulin is a powerful growth  and storage  signal. In the right context—after a meal—it helps muscles and the liver absorb glucose, promotes glycogen storage, and tempers the liver’s own glucose output. When insulin is chronically elevated , however, tissues become less responsive (insulin resistance), the pancreas compensates by producing even more insulin, and a self‐reinforcing cycle develops. Over time, that cycle intertwines with inflammatory pathways and adverse cell-growth signals. Reviews over the last decade synthesize evidence that hyperinsulinemia is implicated in metabolic inflammation, aging biology, and cancer-promoting processes. E-DMJ PMC How high insulin promotes inflammation (“metaflammation”) Excess energy intake—especially ultra-processed foods rich in refined starches and sugars—promotes fat storage in adipose tissue. As fat cells enlarge, they release danger signals and attract immune cells (particularly macrophages). Those immune cells and stressed adipocytes secrete cytokines like TNF-α , IL-6 , and MCP-1 , which activate inflammatory cascades (NF-κB, JNK). The result is chronic low-grade inflammation  that further impairs insulin signaling in liver, muscle, and fat, raising insulin levels still more. This bidirectional loop—sometimes called metaflammation —is now a central model for obesity-related insulin resistance. Nature+1 PMC Clinically, you can sometimes “see” the loop using simple markers. Waist circumference tracks visceral adiposity; high triglycerides with low HDL suggest hepatic insulin resistance; high-sensitivity CRP (hs-CRP) is one marker of systemic inflammation. While no single test tells the whole story, the pattern often points to the same biology. The insulin–IGF axis and cancer risk: association, mechanism, and nuance. Lower insulin levels reduce cancer risk. Cancer risk and progression are influenced by many factors, but one repeatedly observed theme is the insulin/IGF-1 axis . Insulin and insulin-like growth factors activate PI3K–AKT–mTOR and MAPK pathways that promote cell survival and proliferation; chronically elevated signaling may create a more permissive environment for tumor initiation and growth. Epidemiologic studies link higher fasting insulin or C-peptide  (a proxy for endogenous insulin secretion) with greater risk of colorectal and certain endocrine-related cancers, and diabetes itself is associated with increased colorectal cancer risk. Mechanistic reviews and large observational syntheses converge on this axis as biologically plausible and clinically relevant, though causality and effect sizes vary by tumor type and study design. PMC+1 PubMed The prudent takeaway is not that insulin “causes” cancer in a simple linear way, but that metabolic health—lower fasting insulin, less visceral adiposity, improved insulin sensitivity—likely shifts risk in the right direction. Not all 'health foods' are very healthy, at all Practical ways to lower insulin and calm inflammation 1) Choose a dietary pattern that blunts insulin spikes— and  is sustainable Two broad strategies consistently help: Mediterranean-style eating.  High in vegetables, legumes, nuts, fish, olive oil, and minimally processed whole grains, this pattern is associated with lower insulin resistance and improved cardiometabolic markers—independent of weight loss. Recent syntheses show better HOMA-IR and post-challenge insulin sensitivity with higher adherence. PMC BioMed Central Lower glycemic load (GL) approaches.  Emphasizing fiber-rich carbohydrates, intact whole grains, legumes, and reduced refined starch/sugar leads to smaller post-meal glucose and insulin excursions. A large evidence review suggests low-GI/GL dietary patterns produce modest but meaningful improvements in glycemic control, lipids, blood pressure, adiposity, and inflammation—particularly in people with diabetes. PMC No single macronutrient ratio fits everyone, and trials differ on whether lowering glycemic index/load independently reduces inflammatory cytokines. That said, prioritizing fiber-rich, minimally processed foods is a robust, pragmatic way to reduce both insulin demand and inflammatory tone. PubMed A word on intermittent fasting (IF) and time-restricted eating (TRE).  IF can lower fasting insulin and improve insulin sensitivity for many people, in part by extending periods of low insulin (“metabolic switching”). A major review and randomized trials—especially early time-restricted feeding—support improvements in insulin sensitivity and related risk markers. However, IF is not universally superior to other calorie-controlled approaches; the “best” method is the one you can sustain safely. New England Journal of Medicine Nature Fiber is your friend.  Soluble fiber slows glucose absorption, feeds the gut microbiome, and yields short-chain fatty acids that improve insulin signaling and inflammatory tone. Recent reviews and trials show that higher fiber intake—particularly from whole foods—supports insulin sensitivity and glycemic control. MDPI 2) Move your body—consistently Regular physical activity is a potent insulin sensitizer. Meta-analytic data show that aerobic  and combined  (aerobic + resistance) programs lower fasting insulin and HOMA-IR; resistance-only programs can still help (especially for muscle mass and glucose disposal), but combined training generally produces the most reliable improvements in insulin biology. Aim for at least 150–300 minutes/week of moderate aerobic activity plus 2–3 sessions/week of resistance training. PMC 3) Lose a little (or a lot) of visceral fat Even 5–10% weight loss  can substantially reduce fasting insulin and inflammation, with larger losses (when appropriate and safe) yielding larger metabolic dividends. In people with prediabetes, an intensive lifestyle program targeting ~7% weight loss and regular activity cut progression to type 2 diabetes by 58%  over ~3 years—far outperforming metformin in that trial—underscoring how strongly lifestyle affects insulin resistance risk. New England Journal of Medicine 4) Sleep like it’s your job Short or disrupted sleep impairs insulin signaling after just a night or two, and chronic sleep curtailment promotes weight gain and insulin resistance via appetite hormones and sympathetic activation. Guarding 7–9 hours of regular, high-quality sleep is a practical, under-appreciated insulin-lowering intervention. The Lancet 5) Tame chronic stress Psychophysiologic stress raises counter-regulatory hormones (cortisol, catecholamines) that antagonize insulin. Mind-body practices, social connection, and exposure to daylight and nature are not mere niceties; they alter autonomic tone and can lower cardiometabolic risk over time. (Pair this with the sleep guidance above for compounding benefits.) How (and whether) to measure insulin Glucose-centric tests (fasting glucose, oral glucose tolerance, HbA1c) are standard. Fasting insulin  and HOMA-IR  can add context, especially in earlier stages when glucose still looks “normal.” C-peptide  sometimes helps when teasing out endogenous insulin production (e.g., differentiating pancreatic reserve in diabetes phenotypes) and has been used in research on cancer risk, but it’s not a routine cancer screen. Discuss with your clinician which tests, if any, will change management for you personally. In my practice, I check insulin levels simultaneously with glucose and HgA1c. By doing this, I get a good view into past metabolic activity with the HgA1c, present situation with the blood glucose, and future issues with the Insulin level. Safety and special situations If you’re on glucose-lowering medications (especially insulin or sulfonylureas), dietary shifts and fasting protocols require medical supervision  to avoid hypoglycemia. People with eating disorders, frailty, pregnancy, or certain endocrine conditions need tailored plans. For many, the safest and most sustainable first steps are Mediterranean-style meals, more daily movement, better sleep, and stress hygiene. A pragmatic 6-week blueprint Plate pattern at each meal:  half non-starchy vegetables; a palm-sized portion of protein; a thumb-sized portion of healthy fat; and a fist-sized portion of intact, fiber-rich carbs (or fruit). Fiber target:  work toward ≥30–40 g/day from legumes, vegetables, whole grains, nuts, seeds, and fruit. Glycemic load swaps:  replace refined grains and sugary beverages with water/tea/coffee (minimal sweetener), steel-cut oats or barley, intact brown rice or quinoa, lentils/beans. PMC Movement “minimum viable dose”:  30 minutes brisk walking most days + two short resistance sessions (push-pull-legs basics). PMC Sleep routine:  fixed sleep/wake times, dim evening light, cool/dark bedroom, morning daylight. The Lancet Optional TRE trial:  consider a 10–12-hour eating window (e.g., 8 am–6 pm) for 3–4 weeks; avoid aggressive fasting if you use insulin/secretagogues or have a history of disordered eating. Nature Track what matters:  waist circumference, fasting triglycerides/HDL ratio, and—if appropriate—fasting insulin or HOMA-IR with your clinician every few months. Vitamins, Minerals and other Supplements: These will be covered in subsequent Blogs . Bottom line Lowering chronically elevated insulin is not about chasing a number; it is about changing the terrain  in which inflammation and insulin resistance take root—and where cancer-promoting signals can gain a foothold. Nutrient-dense, lower-GL eating; fiber; consistent movement; adequate sleep; and stress control are the most durable levers we have. They are also the least expensive and the most broadly beneficial across chronic disease domains. References Zhang AMY, et al. Hyperinsulinemia in Obesity, Inflammation, and Cancer.   Diabetes Metab J.  2021. doi:10.4093/dmj.2020.0250. E-DMJ Szablewski L. Insulin Resistance: The Increased Risk of Cancers.   Int J Mol Sci.  2024. (Open access.) PMC Li M, et al. Trends in insulin resistance: insights into mechanisms and therapeutics.   Signal Transduct Target Ther.  2022. Nature Guria S, et al. Adipose tissue macrophages and their role in obesity-induced inflammation and insulin resistance.   Front Endocrinol.  2023. PMC Sethi JK, et al. Metabolic Messengers: tumour necrosis factor (TNF).   Nat Metab.  2021. Nature Yu GH, et al. Diabetes and Colorectal Cancer Risk.   Cancers (Basel).  2022. PMC Chen L, et al. Circulating C-peptide level is a predictive factor for colorectal neoplasia.   J Gastroenterol Hepatol.  2013 (meta-analysis). PubMed Zhong W, et al. Obesity and endocrine-related cancer: the important role of the IGF system.   Front Endocrinol.  2023. PMC de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease.   N Engl J Med.  2019. New England Journal of Medicine Xie Z, et al. Randomized controlled trial of early time-restricted feeding: improvements in insulin sensitivity and inflammatory markers.   Nat Commun.  2022. Nature Kazeminasab F, et al. Effects of exercise training on insulin resistance: meta-analysis.   BMC Endocr Disord.  2023. PMC Vetrani C, et al. Mediterranean diet adherence and insulin resistance in overweight/obesity.   Nutrients.  2023. PMC Zheng X, et al. Mediterranean diet and cardiometabolic risk: meta-analysis.   BMC Nutr.  2024. BioMed Central Chiavaroli L, et al. Low-GI/GL dietary patterns: effects on glycemic control, lipids, BP, adiposity, and inflammation.   BMJ  (systematic review/meta-analysis), 2021. PMC Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin.   N Engl J Med.  2002. New England Journal of Medicine Subscribe to our Blog   Youtube Channel Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Room Temperature is extremely important in obtaining a good sleep As a physician, I often remind patients that sleep is not just a passive state; it is an active, restorative process essential for health. While many people focus on bedtime routines, caffeine intake, or screen use before bed, fewer realize how profoundly bedroom temperature  can influence sleep quality. Why Temperature Matters in Sleep The human body follows a natural circadian rhythm , which regulates sleep and wake cycles. A key part of this rhythm is the drop in core body temperature  that occurs at night. This cooling signals the brain that it is time to sleep. If the sleep environment is too warm or too cold, it can disrupt this natural process, leading to fragmented sleep or difficulty falling asleep. The Optimal Temperature Range Research suggests that the ideal bedroom temperature for most adults is between 60°F and 67°F (15.5°C–19.5°C) . Within this range, the body can best maintain the slight drop in core temperature necessary for deep, restorative sleep. Temperatures above 70°F (21°C) are associated with more nighttime awakenings, while excessively cold environments can also lead to discomfort and poor sleep. Physiological Basis During sleep onset, blood vessels in the hands, feet, and face dilate to release heat, lowering core body temperature. A cooler environment assists this process. By contrast, a hot room impairs heat dissipation, prolonging sleep latency (the time it takes to fall asleep) and reducing slow-wave and REM sleep. Cold environments may stimulate shivering, which interferes with sleep continuity. Individual Variation The “optimal” temperature can vary based on: Age : Infants and older adults may need slightly warmer environments. Sex and hormones : Women may experience different thermal comfort during menstrual cycles or menopause. Medical conditions : Disorders such as insomnia, sleep apnea, or neuropathy may make individuals more sensitive to thermal stress. Practical Steps for Better Sleep Temperature Set your thermostat : Aim for 60–67°F for adults; 65–70°F for infants and older adults. Bedding choice : Use breathable materials like cotton or bamboo. Avoid heavy blankets in warm weather. Pajamas : Wear lightweight, breathable fabrics to aid heat dissipation. Mattresses and pillows : Cooling gels or ventilated foam can help regulate body heat. Air circulation : Fans and open windows can enhance comfort, especially in humid climates. Warm baths before bed : Surprisingly, a warm bath helps sleep by causing rebound cooling once you get out. Broader Health Implications Maintaining an optimal sleep temperature doesn’t just improve rest—it supports metabolic health, cognitive performance, and emotional regulation. Poor sleep temperature control has been linked to insomnia, cardiovascular strain, and reduced daytime alertness. Conclusion Sleep is one of the most powerful tools we have for health. By keeping your bedroom in the 60–67°F range , you give your body the environment it needs to achieve restorative rest. Simple adjustments to your room’s temperature, bedding, and clothing can lead to profound improvements in sleep quality and overall well-being. Understanding that changing habits is difficult, my general recommendation is to drop the bedroom temperature to 71 degrees, sleep under your blanket, and get used to this temperature. If you begin to sleep better, this may be all you need to do. If you need to drop the temperture below 71 degrees, decrease by 1 degree ever few days until you get to 67 degrees, and then maintain the temperature. References Okamoto-Mizuno K, Mizuno K. Effects of thermal environment on sleep and circadian rhythm. J Physiol Anthropol.  2012;31(1):14. Harding EC, Franks NP, Wisden W. Sleep and thermoregulation. Curr Opin Physiol.  2019;15:7-13. Czeisler CA, et al. Human sleep: its duration and organization depend on its circadian phase. Science.  1980;210(4475):1264-1267. Krauchi K, Deboer T. The interrelationship between sleep regulation and thermoregulation. Front Biosci.  2010;15:604-625. Lan L, Lian Z, Pan L, Ye Q. Neurobehavioral approach for evaluation of office workers’ productivity: the effects of room temperature. Build Environ.  2009;44(8):1578-1588. van Marken Lichtenbelt WD, et al. Cold exposure—a tool to increase energy expenditure in humans. Trends Endocrinol Metab.  2014;25(4):165-167. Raymann RJEM, et al. Skin deep: local heat application increases sleep depth. Sleep.  2008;31(2):191-199. Okamoto-Mizuno K, et al. Effects of humid heat exposure on human sleep stages and body temperature. Sleep.  2004;27(3):420-426. Dautovich ND, et al. Sleep and temperature regulation in aging. Handb Clin Neurol.  2019;167:499-511. Lan L, Lian Z, Lin Y. Comfortably cool bedroom environment facilitates deeper sleep. Build Environ.  2016;103:208-216. Krauchi K, Cajochen C. Body temperatures, sleepiness, and melatonin in young and elderly humans during day and night. J Biol Rhythms.  1997;12(6): 536-546. Link Romanovsky AA. Thermoregulation: some concepts have changed. Functional architecture of the thermoregulatory system.   Am J Physiol Regul Integr Comp Physiol.  2007;292(1):R37-R46. Link Harding EC, et al. The temperature dependence of sleep. Curr Biol.  2018;28(21):3596-3604. Link Magnavita N, et al. Sleep problems and workplace comfort in healthcare workers. Int J Environ Res Public Health.  2018;15(9):1975. Link Badia P, et al. Bright light and body temperature: independent and interactive effects on human sleep. Am J Physiol.  1991;260(3 Pt 2):R422-R430. Link Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

As a physician, I often see patients who struggle with foot pain, especially in the heel. One of the most common culprits is plantar fasciitis , a condition that affects people of all ages but is especially noticeable among those who are on their feet a lot, athletes, and individuals with certain risk factors. Let’s break down what it is, what causes it, how it’s treated, and—most importantly—how you can prevent it. The Plantar Fascia is a tough band of muscles and tendons on the bottom (Plantar Aspect) of the Foot What Is Plantar Fasciitis and Why does it Cause Foot Pain? The plantar fascia  is a thick band of tissue that runs along the bottom of your foot, connecting your heel bone to your toes. Its job is to support the arch of your foot and absorb shock when you walk or run. When this tissue becomes irritated or inflamed, it leads to plantar fasciitis. The hallmark symptom is sharp heel and foot pain , especially when taking the first steps in the morning or after sitting for a while. The plantar fascia is a tough band of tissue that stretches from the forefoot to the heel, and is responsible for maintenance of arch integrity. Causes and Risk Factors Plantar fasciitis usually develops from repeated stress  on the plantar fascia. Several factors increase the likelihood of developing it: Foot mechanics : Flat feet, high arches, or an abnormal walking pattern can place extra stress on the fascia. Overuse : Long-distance running, dancing, or prolonged standing can strain the heel. Improper footwear : Shoes without proper arch support or cushioning can worsen the problem. Age and weight : It’s more common in people between ages 40–60 and in those carrying excess weight, which increases pressure on the fore-foot. The Plantar Fascia is under maximal tension when weight is on the forefoot. Due to persistent mechanical stress resulting from prolonged walking, standing and stretching, the plantar fascia withstands remarkable mechanical challenges during routine activity.  As a result of microtrauma subsequent to jumping, jogging, and running, the plantar fascia can develop  small areas where it is torn from the attachment on the heel. Foot and Hell Pain are a direct result. Symptoms The classic sign is a sharp, stabbing pain at the bottom of the heel . The pain is usually worse in the morning or after periods of rest, but may improve with movement. Over time, the discomfort can become constant if untreated. The pain of plantar fasciitis is usually  stabbing or burning pain in nature,  usually worse in the morning.   The pain seems to be worse when your feet hit the floor after sleep, and the pain eases with motion and mobility. The pain will come and go, worse with certain types of shoes and with pressure on localized areas. Treatment Options The good news is that most cases of plantar fasciitis improve with conservative treatment : Rest and activity modification : Reducing high-impact activities gives the fascia time to heal. Ice and anti-inflammatory measures : Applying ice or taking non-steroidal anti-inflammatory drugs (NSAIDs) can reduce pain and swelling. Stretching and physical therapy : Gentle calf stretches, plantar fascia stretches, and strengthening exercises for the foot and ankle can help. Supportive footwear and orthotics : Shoes with good arch support, cushioned soles, or custom orthotic inserts take stress off the fascia. Night splints : Wearing a splint that keeps the foot flexed overnight can stretch the fascia and lessen morning pain. In more severe or persistent cases, other treatments such as steroid injections, shockwave therapy, or surgery  may be considered, but these are reserved for people who do not respond to conservative measures. Prevention Strategies Preventing plantar fasciitis often comes down to protecting your feet from stress : Wear shoes with good cushioning and arch support. Replace athletic shoes regularly, especially if you run or walk often. Stretch your calves and feet before and after exercise. Maintain a healthy weight to reduce pressure on your feet. Avoid walking barefoot on hard surfaces for prolonged periods. Final Thoughts Plantar fasciitis can be frustrating, but with the right approach, it is manageable and often curable without invasive treatment. By paying attention to your footwear, body mechanics, and activity habits, you can both recover from plantar fasciitis and reduce the risk of it coming back. References Buchbinder R. Plantar fasciitis. N Engl J Med.  2004;350(21):2159-2166. Riddle DL, Schappert SM. Volume of ambulatory care visits and patterns of care for patients diagnosed with plantar fasciitis. Foot Ankle Int.  2004;25(5):303-310. League AC. Current concepts review: plantar fasciitis. Foot Ankle Int.  2008;29(3):358-366. Cutts S, Obi N, Pasapula C, Chan W. Plantar fasciitis. Ann R Coll Surg Engl.  2012;94(8):539-542. Martin RL, Irrgang JJ, Conti SF. Outcome study of subjects with insertional plantar fasciitis. Foot Ankle Int.  1998;19(12):803-811. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

When is abdominal pain an emergency? Abdominal pain can be unsettling at any stage of life. Many causes are harmless, but some need urgent care. This post explains when to worry about abdominal pain and when to see a doctor . It follows an evidence-based approach and uses insights from reputable medical sources. Understanding Abdominal Pain Abdominal pain  is any discomfort felt anywhere between the chest and groin. Because the abdomen contains many organs, pain can come from the digestive system, muscles or even organs outside the belly. The severity does not always match the seriousness of a chronic condition and may pass or persist depending upon the cause. Types of Abdominal Pain: Acute vs. Chronic Acute abdominal pain starts suddenly and lasts hours or days. Causes  range from infections to injuries.  Chronic pain that persists for weeks or longer and is often due to underlying conditions such as irritable bowel syndrome or ulcers. Persistent abdominal pain always warrants medical evaluation. Menstrual cramps can be mild or severe, and may require medical attention if persistent or intense. Common Causes of Abdominal Pain Digestive issues:  Gas, indigestion, constipation and diarrhea often cause temporary pain. Eating too quickly, food poisoning, or food intolerances may also lead to discomfort. Inflammation: Infections like viral gastroenteritis, peptic ulcers, or urinary tract infections can cause inflammatory pain. Female reproductive cycle:  Menstrual cramps and ovulation pain are common sources of lower abdominal discomfort. Other organs:  Problems in the chest (heart attack), pelvis, or back can mimic stomach pain.  When to Worry About Abdominal Pain Most bellyaches resolve with time, but certain features suggest  a more serious issue . Pay attention to the duration and severity of pain and any accompanying symptoms. Pain That Persists or Worsens Unexplained abdominal pain that is persistent or severe requires medical attention . If the pain follows trauma, occurs during pregnancy or in young children, seek prompt evaluation.  Persistent pain after surgery or in older adults may indicate bowel obstruction or another complication. It is always best to seek medical attention if there is any question of urgency or emergency When To See A Doctor About Abdominal Pain Seek a doctor’s assistance immediately if abdominal pain is accompanied by: Fever: Persistent fever can signal infection or inflammation. Nausea or vomiting: Continuous nausea or vomiting, especially with inability to keep liquids down, is a red flag. Blood in stool, urine or vomit:  Blood can indicate bleeding in the gastrointestinal tract. Jaundice:  Yellowing of the skin and eyes may suggest liver or gallbladder disease. Swelling and tenderness: A swollen or tender abdomen requires evaluation. Shortness of breath or chest pressure: Pain associated with difficulty breathing or chest pain could reflect heart or lung problems. Inability to pass gas or stool: Bloating, constipation, and an inability to pass gas can signal bowel obstruction When Is Abdominal Pain an Emergency? Some situations demand immediate emergency care. Recognizing these signs can be lifesaving. Signs You Should Go to the ER Immediately According to the Mayo Clinic , you should call emergency services if your abdominal pain is severe and accompanied by trauma, chest pressure, or pain.  Nurse evaluating an ER patient with abdominal pain. Go to the emergency department if you experience: Severe, sudden pain:  A sudden onset of intense pain that makes movement difficult is concerning. Pain with fever or chills : Fever may point to infection or inflammation. Persistent pain in the lower right abdomen: This may indicate appendicitis. Chest pressure or shortness of breath:  Pain radiating to the chest, shoulder, or back can mimic heart attack. Pain with bloody vomiting or black stools: These signs suggest internal bleeding. Bloating with inability to pass gas or stool: Could be a bowel obstruction. Conditions That Require Urgent Care Several conditions necessitate urgent evaluation . Appendicitis Pain  often begins near the belly button and migrates to the lower right abdomen. It may start slowly and worsen over 12-24 hours.  Appendicitis is more common in teenagers and young adults. Bowel Obstruction Bloating, constipation and inability to pass gas, especially in people with previous abdominal surgery, suggest obstruction. Acute Pancreatitis Pain starts in the upper abdomen and worsens after eating. Symptoms may include fever and rapid pulse. Kidney Stones Sharp, cramping pain in the lower abdomen or back that peaks rapidly, often early in the morning, could signal kidney stones. Gallbladder Infection Severe right upper quadrant pain with fever and jaundice may indicate cholecystitis . Not All Abdominal Pain Requires An Emergency Room Visit.  Your primary care doctor can evaluate many conditions and decide if specialist care is needed. Schedule a doctor's visit if your pain lasts more than a few days or if it worries you.  Seek care sooner if you have underlying medical problems or are older, pregnant, or immunocompromised. What Your Primary Care Provider Can Help With Your doctor can diagnose and treat conditions like indigestion, constipation, food intolerance, or mild infections.  They may prescribe medication, recommend lifestyle changes, or order basic tests. If you have chronic conditions such as irritable bowel syndrome, your doctor can help manage symptoms and refer you to a specialist if needed. When to Ask for a Specialist Referral You might need a gastroenterologist  or surgeon if your symptoms are persistent, unexplained, or linked to structural issues.  Conditions like inflammatory bowel disease, gallstones, or hernias often require specialist evaluation. Recurrent pain in older adults may call for imaging studies to rule out cancer or vascular problems. Diagnostic tests for abdominal pain can range from blood tests to ultrasound imaging. What to Expect During a Medical Evaluation Questions You'll Be Asked Health professionals will ask about the location, intensity, and duration of your pain. They may inquire about your diet, bowel habits, and any triggers or relieving factors.  Possible Tests or Imaging Your doctor may perform blood tests , urine tests or stool studies.  Imaging like ultrasound or CT scans can reveal gallstones, appendicitis or other structural problems. Endoscopy may be used to examine the stomach or intestines.  The tests ordered depend on your symptoms, age and medical history. How to Track Your Symptoms at Home A symptom diary can provide valuable insight. Be sure to include: Time: Record when the pain occurs and how long it lasts. Location:  Note where you feel pain and whether it spreads. Severity:  Use a scale from 0 to 10 to rate intensity. Triggers or relief: Track foods, activities, or bowel habits that affect pain and any medications that help. Final Thoughts On When Should You Worry About Abdominal Pain Abdominal pain  is a common complaint across all ages.  Most cases are minor, but persistent or severe pain or pain with concerning symptoms should prompt a medical evaluation.  Understanding when abdominal pain is an emergency helps you act quickly and reduces the risk of complications. Listen to your body and seek care when something feels wrong.  At Longwood, Florida-based Stages of Life Medical Institute , our pain specialists diagnose all forms of abdominal pain and help guide appropriate treatment.  To become a new patient, simply click her e. Subscribe to our Blog   Youtube Channel Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

A different kind of Weight Management. Prevention of Dementia and Diabetes Audience:  patients and families curious about whether GLP-1–based medicines (e.g., semaglutide, tirzepatide, liraglutide) might help protect brain health—especially given growing discussion of Alzheimer’s disease as “type 3 diabetes.” The takeaway up front As a physician, I see two parallel truths emerging from recent science. First, Alzheimer’s disease and other dementias are strongly linked to metabolic dysfunction—especially insulin resistance in the brain, sometimes labeled “type 3 diabetes.”  Second, a class of diabetes and weight-management medicines called GLP-1 receptor agonists (GLP-1 RAs)  shows early but increasingly consistent signals that they may lower dementia risk in people with type 2 diabetes, and possibly slow specific biological changes of Alzheimer’s in small clinical trials. These signals are not yet the same as definitive proof of prevention, but they are promising enough to merit discussion with your clinician if you’re already a candidate for these drugs for diabetes, obesity, or cardiometabolic risk. JAMA Network+3MDPI+3ScienceDirect+3 Why Alzheimer’s has been called “type 3 diabetes” For more than a decade, researchers have observed that insulin signaling in the brain  is impaired in Alzheimer’s disease (AD). Insulin helps neurons use glucose, modulates synapses (the “wiring” that underlies memory), and dampens inflammatory cascades. When brain insulin signaling falters, glucose metabolism drops, oxidative stress rises, amyloid and tau processing can worsen, and microglia (the brain’s immune cells) are more likely to stay in an inflammatory state. These patterns have led many scientists to frame AD as a brain-specific insulin-resistant state , colloquially “type 3 diabetes.” While not every expert embraces the term, multiple recent reviews detail the mechanistic links. MDPI+2ScienceDirect+2 Enter GLP-1: from pancreas to brain GLP-1  is a hormone made in the gut and the brain that boosts insulin secretion when glucose is high, tempers glucagon, slows gastric emptying, and promotes satiety. GLP-1 receptor agonists (GLP-1 RAs)  are long-acting versions of this signal (liraglutide, semaglutide, dulaglutide, and the dual GIP/GLP-1 agent tirzepatide) developed to treat type 2 diabetes and, more recently, obesity. Beyond glucose and weight, GLP-1 signaling appears to modulate neuroinflammation, improve neuronal energy handling, and support vascular health , all relevant to neurodegeneration. Nature+2PMC+2 Do these medicines reach the brain? Evidence suggests that GLP-1 pathways influence the central nervous system via multiple routes: some agents and/or their downstream effects reach or affect the brain and blood–brain barrier , altering glucose transport, microglial activation, and synaptic function in preclinical and early human studies. Quantitative BBB penetration differs by molecule and remains an active research area. PMC+1 What the human data show so far. Why GLP-1 agents, like Zepbound, help with sleep apnea, diabetes, heart disease, and weight loss 1) Large real-world observational studies (association ≠ proof) In 2025, a Nature Medicine  analysis of >2 million U.S. veterans with diabetes mapped outcomes after initiating GLP-1 RAs vs several comparators. Among many findings, GLP-1 use was associated with lower risk of Alzheimer’s disease  and other neurological outcomes compared with usual care, with effect sizes varying by comparator drug class. Observational designs can’t prove causality, but the signal aligns with growing literature. PubMed A JAMA Network Open  cohort (60,860 adults with type 2 diabetes and obesity) reported that semaglutide or tirzepatide  users had lower risks of dementia, stroke, and all-cause mortality  than patients treated with other glucose-lowering drugs. Again, this is association, not proof, but it’s consistent and clinically meaningful. JAMA Network Several complementary analyses—including the largest direct comparison of GLP-1 RAs vs metformin  as initial therapy—suggest GLP-1 drugs may reduce overall and Alzheimer’s-type dementias  more than metformin in people with type 2 diabetes. These studies use modern matching methods but remain observational. BMJ Disease Reviews Finally, a systematic review and meta-analysis in JAMA Neurology (2025)  pooling randomized cardiometabolic trials found no overall cognitive/dementia benefit across all cardioprotective diabetes drugs , but GLP-1 RAs stood out with a statistically significant reduction in incident dementia  in subgroup analyses—important but still Can GLP-1 Drugs Help Prevent Dementia? A Physician Explains GLP-1 Medications help with both diabetes and obesity while preventing neuronal damage resulting in Dementia You may have heard the terms GLP-1 agents, Alzheimer’s, dementia, “type 3 diabetes”—wondered how they connect, and whether drugs designed for diabetes (or weight loss) might also protect your brain. Here's what I, as a physician, see in the current scientific landscape. I’ll try to be optimistic where the data warrant it, but also clear about what remains uncertain. Background: Dementia, Alzheimer’s & “Type 3 Diabetes” Insulin Resistance of Diabetes type III Dementia—especially Alzheimer’s disease (AD)—is a progressive decline in cognition, memory, planning, and daily functioning. Currently, there is no cure, though some medications slow progression in select patients. Prevention, or delaying onset, is thus a major clinical goal. “Type 3 diabetes”  is a term used to underscore a growing body of evidence that Alzheimer’s involves insulin resistance in the brain, impaired glucose metabolism, mitochondrial dysfunction, chronic inflammation, and oxidative stress—much like in type 2 diabetes. The idea is not  that Alzheimer’s is literally the same as type 2 diabetes, but that many pathological features overlap. ScienceDirect+3MDPI+3PMC+3 Key points: The brain uses glucose as its primary fuel. If insulin signaling is disrupted, neurons may suffer energy deficits. Insulin has roles in synaptic plasticity, modulating tau phosphorylation, amyloid metabolism, and reducing oxidative stress. PMC+3Frontiers+3Diabetes Journals+3 People with type 2 diabetes (T2DM) have significantly increased risk of AD/dementia. MDPI+2PMC+2 Thus, any intervention that improves insulin sensitivity, reduces inflammation, supports mitochondrial health, and perhaps modulates amyloid/tau pathology has theoretical potential in dementia prevention. What Are GLP-1 Agents? GLP -1 Agents affect much more than appetite and weight GLP-1 (glucagon-like peptide‐1) is a hormone made in the gut (and to some extent in the brain) that helps with: stimulating insulin secretion when glucose is high; suppressing glucagon; slowing gastric emptying; promoting satiety; and possibly having direct effects in other organs (heart, brain, immune system). GLP-1 receptor agonists (GLP-1 RAs) are medications modeled on this hormone (or its effects). They are used in T2DM, obesity, and increasingly in cardiovascular risk reduction. Examples: liraglutide, semaglutide, dulaglutide, occasionally dual agents (GLP-1 + GIP like tirzepatide). These agents have multiple effects relevant to brain health: improved glycemic control (lowering glucose spikes, avoiding hyperglycemia) weight loss, which reduces many risk factors (vascular disease, hypertension, dyslipidemia) possible reduction of systemic inflammation possible direct neural effects: crossing—or affecting—the blood brain barrier; reducing amyloid and tau pathology; improving neuronal insulin signaling; preserving mitochondrial function; reducing oxidative stress. Frontiers+2PMC+2 Mechanistic and Animal Evidence Before we look at clinical data, the animal and in vitro work is reassuring—and helps suggest how  GLP-1 might work in the brain. Amyloid & tau modulation : In mouse models of AD, GLP-1 RAs reduce amyloid β oligomer levels and plaque load; reduce tau hyperphosphorylation. Diabetes Journals+1 Neuroinflammation / oxidative stress : GLP-1 agents appear to reduce microglial activation, lower inflammatory cytokines, improve antioxidant defenses in brain tissue. Frontiers+2PMC+2 Mitochondrial health and neuronal energy : Some studies show improved mitochondrial function, decreased dysfunction, improved neuronal metabolic reprogramming in response to insulin resistance when GLP-1 pathways are engaged. BioMed Central+1 Brain insulin signaling : GLP-1 RAs in animal models can improve insulin signaling in neurons, enhancing glucose uptake and utilization in brain regions affected in AD. PMC+1 So mechanistically, there is  plausibility. Animal studies are consistent across multiple models. But as always, animal studies are not enough to guarantee human benefits. Human / Clinical Evidence: What We Know Now we move from what could  happen, to what seems  to happen in people. Observational Studies & Real‐World Data These are large database studies, often with millions of patients, comparing dementia incidence (or cognitive decline) among people with T2DM (or obesity) using GLP-1 RAs vs other therapies. A recent JAMA article showed that among people with T2DM, use of GLP-1 RAs was associated with a statistically significant decrease in dementia risk compared with other antidiabetic drugs. JAMA Network Another large observational study found that people with T2DM and obesity using semaglutide or tirzepatide had lower risk of dementia, stroke, and all-cause mortality compared to those on other glucose‐lowering agents. Alzheimer's & Dementia Journals+2The Lancet+2 A meta-analysis pooling many clinical trials (though mostly for diabetes endpoints) suggested that GLP-1 RAs (versus placebo or other drugs) may reduce risk of dementia among diabetics. The Lancet+1 Pros of observational data: large numbers, real world; cons: possible confounding (people who are prescribed GLP-1 agents may differ in many ways), reverse causality, indication bias, duration of follow-up may be short for dementia (often slow developing). Randomized Trials & Clinical Interventions These are more limited so far, but growing. The ELAD trial  (Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease) was a Phase 2b randomized, double-blind, placebo-controlled study in ~204 patients with mild AD. Over one year, liraglutide did not  significantly improve the primary endpoint (change in cerebral glucose metabolic rate in certain brain regions), but secondary endpoints—including brain volume loss, and cognitive measures—showed benefit: ~50% less loss in several brain regions compared to placebo; also slower decline on cognitive tests. AAIC 2026 A comparative effectiveness analysis of second-line diabetes medications in real‐world registry (Danish registry) comparing GLP-1 RAs to other agents found a protective effect of GLP-1 RAs vs certain other second-line drugs over 5 years, though not against all  comparators. arXiv Systematic Reviews / Meta-analyses A recent systematic review on “type 3 diabetes” draws together evidence of overlapping mechanistic pathways, supporting the idea that agents targeting insulin resistance (including GLP-1 RAs) might have benefit. PMC+2PMC+2 Another meta-analysis (in JAMA Neurology) pooling more than 160,000 participants across many trials of glucose-lowering agents found that GLP-1 drugs were among the few classes associated with reductions in Alzheimer’s disease and other dementias in subgroup analyses. alzinfo.org +1 Putting It Together: What It Might Mean for You As your physician, here's how I think about this evidence, and how it might apply in your case. Potential Benefits (What We Can Hope For) Slowing or delaying onset of dementia , especially in people with risk factors: T2DM, obesity, metabolic syndrome, hypertension. If GLP-1 agents reduce incidence (as observational studies suggest), that may translate into clinically meaningful delay. Preserving brain structure and function , as suggested by trials like ELAD: less loss of brain volume, possibly less cognitive decline, at least in early/mild disease. Reducing vascular risk : many cases of dementia are mixed, including vascular contributions. GLP-1 agents help with cardiovascular risk, weight, hypertension, dyslipidemia—all of which affect brain blood vessels. Multiple mechanisms : the combination of improved glucose/insulin signaling + reduced inflammation + mitochondrial support + potential direct effects on amyloid/tau. This multipronged approach is promising, since dementia is multifactorial. Secondary benefits : weight loss, better diabetes management, improved overall metabolic health—benefits we already accept for GLP-1 agents even ignoring brain effects. Limitations & Unknowns While promising, there remain many uncertainties: Causality not yet proven : Many studies are associative. Randomized controlled trial (RCT) evidence is limited and not yet definitive for prevention. Duration of effect : Dementia develops over many years (often decades). Most trials and observational follow-ups so far are in the range of 1-5 years. We don’t yet know how long GLP-1 agents must be taken, or at what age, to achieve durable prevention. Selection of patients : It may be that benefits are strongest in those with early metabolic dysfunction, mild cognitive impairment, or early Alzheimer’s disease, rather than in advanced dementia. Timing likely matters. Drug choice, dose, and penetration : Differences among GLP-1 RAs in ability to affect the brain (blood–brain barrier penetration, receptor binding, half-life, dosing) may influence outcomes. Not all agents may perform equally in this regard. Side effects and risks : Though GLP-1 agents are generally well tolerated, they carry risk of gastrointestinal effects, possible rare pancreatitis, effects on gallbladder, etc. Also cost, access, monitoring. These must be weighed, especially in older patients or those with compromised renal or hepatic function. Non-diabetic populations : Most data so far are in people with T2DM or obesity. It's not yet established whether GLP-1 RAs will benefit people without those risk factors in preventing dementia. Clinical Implications & What I Might Recommend If you are interested in whether GLP-1 drugs might be protective for your brain, here’s how I’d think about integrating the current data into individualized care. Assess risk factors : Do you have type 2 diabetes? Prediabetes? Obesity? Hypertension? Dyslipidemia? Family history of AD? ApoE status (if tested)? These modify risk and may help decide how strongly to consider GLP-1 therapy for brain protection. Evaluate current indications : If you already qualify for a GLP-1 agent for diabetes, obesity, or cardiovascular risk, this brain effect adds more rationale. If you don’t, the risk vs benefit profile is different. Monitor cognition and brain health : If using GLP-1 agents, baseline cognitive testing (memory, executive function) and periodic follow-up may help document whether there is slowing of decline (though in routine practice, this is limited). Lifestyle remains foundational : Diet, exercise, sleep, managing cardiovascular risks remain essential. GLP-1 agents are not a substitute for those proven preventive measures. Research enrollment : If possible, enrolling in clinical trials designed to test GLP-1 RAs for dementia prevention or early AD may help (and give access to more intensive monitoring). Shared decision-making : If considering off‐label or “prevention” use, open discussion of uncertain benefit, possible side effects, cost, monitoring is essential. Where Research Is Heading / What to Watch For Larger RCTs in non-diabetic or prediabetic populations specifically targeting cognitive decline or dementia as endpoints. Head-to-head trials of different GLP-1 agents to see which have better brain penetration and efficacy. Studies of biomarkers (amyloid PET, tau imaging, MRI volumetrics) to detect early structural/functional changes. Long-term follow-ups (5-10+ years) to see if cognitive effects translate into reduced incidence of dementia, delayed institutionalization, preserved quality of life. Safety and tolerability in older age groups, polypharmacy, kidney, and hepatic impairment. So: Should You Use a GLP-1 Agent for Dementia Prevention? Here’s how I interpret the balance of evidence as of now. If you have type 2 diabetes or obesity and  are already considering a GLP-1 agent for metabolic reasons, then the potential brain benefits are a compelling additional advantage. If you do not  have metabolic disease, the idea of using GLP-1 purely for dementia prevention is more speculative. It might become standard in future, but I wouldn’t yet recommend it off-label purely for that purpose outside of research settings. Age, comorbidities, risk of side effects, cost, and your personal risk tolerance all matter. For someone with moderate risk, early metabolic dysfunction, family history, preserving cognition may tip the scale. Summary Alzheimer’s disease shows many features of insulin resistance in the brain, metabolic dysfunction, inflammation, oxidative stress: that’s the “type 3 diabetes” hypothesis. GLP-1 receptor agonists have multiple mechanisms that could  beneficially intervene in those pathological processes. Animal and mechanistic studies are strong; observational and early clinical trial data are promising. But we do not  yet have definitive proof in prevention — especially in long durations, in individuals without metabolic disease. If you are already using GLP-1 agents for metabolic disease, the potential cognitive benefits provide an added rationale. If not, it remains an area to watch and perhaps participate in trials. References Bae CS, et al. The Role of Glucagon-Like Peptide 1 (GLP-1) in Type 3 Diabetes: Glucose Metabolism, Amyloid, and Insulin Resistance in Alzheimer’s Disease . International Journal of Molecular Sciences.  2017;18(4):919. doi:10.3390/ijms18040919. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5713459/   PMC Atabi F, et al. A systematic review on type 3 diabetes: bridging the gap between diabetes and Alzheimer’s disease.   International Journal of Neuroscience.  2025. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12382249/   PMC Peng Y, et al. True or false? Alzheimer’s disease is type 3 diabetes.   Ageing Research Reviews.  2024; doi:10.1016/j.arr.2024.101051. Available from: https://www.sciencedirect.com/science/article/pii/S1568163724002010   ScienceDirect Du H, et al. The mechanism and efficacy of GLP-1 receptor agonists in Alzheimer’s disease.   Frontiers in Endocrinology.  2022;13:1033479. doi:10.3389/fendo.2022.1033479. Available from: https://www.frontiersin.org/articles/10.3389/fendo.2022.1033479/full?utm_source=chatgpt.com   Frontiers Hölscher C. GLP-1 class drugs show clear neuroprotective effects in first clinical trials in AD and PD patients.   Neuroscience & Biobehavioral Reviews.  2024. Available from: https://www.sciencedirect.com/science/article/pii/S0028390824001217   ScienceDirect Tang B, et al. Comparative effectiveness of glucagon-like peptide-1 receptor agonists and other second-line glucose-lowering agents for dementia outcomes in type 2 diabetes mellitus: A cohort study.   eClinicalMedicine.  2024;79:102635. doi:10.1016/j.eclinm.2024.102635. Available from: https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(24)00268-2/fulltext   The Lancet “GLP-1 Medications May Lower Dementia Risk, Research Suggests.” JAMA.  2025; (April). Anderer S, et al. Available from: https://jamanetwork.com/journals/jama/fullarticle/2833663   JAMA Network Wang W, et al. Associations of semaglutide with first-time diagnosis of dementia in people with type 2 diabetes.   Alzheimer’s & Dementia.  2024. Available from: https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.14313   Alzheimer's & Dementia Journals Edison P, et al. Evaluating the Effects of the Novel GLP-1 Analogue Liraglutide in Alzheimer’s Disease (ELAD): Phase 2b randomized, double-blind, placebo-controlled trial.  Alzheimer’s Association International Conference (AAIC), 2024. Summary available from: https://aaic.alz.org/releases-2024/glp-drug-liraglutide-may-protect-against-dementia.asp   AAIC 2026 Li S, et al. GLP-1R as a potential link between diabetes and Alzheimer’s disease: Mechanistic insights and therapeutic opportunities.   Frontiers in Aging Neuroscience.  2025; Article 1601602. Available from: https://www.frontiersin.org/journals/aging_neuroscience/articles/10.3389/fnagi.2025.1601602/full   Frontiers Meng X, et al. Type 3 diabetes and metabolic reprogramming of brain neurons.   Molecular Medicine.  2025;31(1):101. doi:10.1186/s10020-025-01101-z. Available from: https://molmed.biomedcentral.com/articles/10.1186/s10020-025-01101-z   BioMed Central Monney M, et al. GLP-1 receptor agonists effect on cognitive function in diabetes: a systematic‐review / meta‐analysis.   Neuroscience & Biobehavioral Reviews.  2023; S1262-3636(23)00052-6. Available from: https://www.sciencedirect.com/science/article/pii/S1262363623000526   ScienceDirect “Weight Loss Drugs May Protect Against Alzheimer’s.” Alzinfo.org .  Reddin C, et al. 2025. Available from: https://www.alzinfo.org/articles/treatment/weight-loss-drugs-may-protect-against-alzheimers/   alzinfo.org “How GLP-1s Could Transform Alzheimer’s Treatment.” BrightFocus Foundation.  2025. Available from: https://www.brightfocus.org/resource/how-glp-1s-could-transform-alzheimers-treatment/   BrightFocus Foundation Kciuk M, et al. Alzheimer’s Disease as Type 3 Diabetes.   International Journal of Molecular Sciences.  2024;25(22):11955. doi:10.3390/ijms252211955. Available from: https://www.mdpi.com/1422-0067/25/22/11955/   MDPI Hölscher C. Protective effects of GLP-1 receptor agonists in neurodegeneration.  In: Neurotherapeutics. 2024. (“GLP-1 class drugs show clear protective effects…”). Available from: https://www.sciencedirect.com/science/article/pii/S0028390824001217   ScienceDirect Frontiers review: Du H, et al. (as above) discussing GLP-1 RAs’ mechanisms (ref. 4), especially insulin resistance in brain and oxidative stress. Frontiers Insulin resistance as molecular link between diabetes and AD. World Journal of Diabetes.  2024;15(7):1430-1445. Du C-T, et al. Available from: https://www.wjgnet.com/1948-9358/full/v15/i7/1430.htm   WJGNet The Danish registry study: Nerissa Nance, Andrew Mertens, et al. Applying the causal roadmap to longitudinal national registry data: a case study of second-line diabetes medication and dementia.  arXiv preprint. 2023. Available from: https://arxiv.org/abs/2310.03235   arXiv “GLP-1 receptor agonists effect on cognitive function in diabetes: a systematic review / meta-analysis.” (Monney et al., 2023) — repeated to emphasize the evidence in people with T2DM. Available from: https://www.sciencedirect.com/science/article/pii/S1262363623000526   ScienceDirect Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician

Statins, GLP-1, and Metabolic Health: What Patients Should Know GLP-1 Medicines are beneficial in many ways If you take a statin to lower cholesterol, you’re in good company: statins are among the most widely prescribed medicines in the world. They reduce LDL (“bad cholesterol”) and convincingly lower the risk of heart attacks and strokes. That part is not in dispute. What is  being actively studied is how statins may influence blood-sugar control and a gut-derived hormone called GLP-1 (glucagon-like peptide-1), which helps regulate insulin release, appetite, and inflammation. Because GLP-1 also intersects with brain and blood-vessel health, patients often ask whether statins could nudge them toward diabetes or even affect cognition over time. Below is a plain-spoken tour of the best evidence we have today, plus practical steps you can take with your clinician to protect both your heart and your metabolism. GLP-1 in one minute GLP-1 is a hormone released by intestinal L-cells after you eat. Think of it as a “meal messenger” that: Helps the pancreas release insulin when glucose rises Tamps down glucagon (reduces liver glucose output) Slows stomach emptying so glucose rises more gently Sends satiety signals to the brain Boosting GLP-1 signaling—either by mimicking it (GLP-1 receptor agonists) or prolonging native GLP-1 (DPP-4 inhibitors)—improves glycemic control and reduces cardiometabolic risk in many patients. AHA Journals+1 A new twist: statins, the microbiome, bile acids… and lower GLP-1 GlP-1 influence many organs, including the liver, brain and stomach In 2024, a high-quality translational study reported that statins can aggravate insulin resistance by reducing circulating active GLP-1 levels —and that the effect appears to be microbiome-dependent . Mechanistically, statins altered the bile-acid pool (notably lowering ursodeoxycholic acid, UDCA), which reduced signaling through the TGR5 receptor on intestinal cells, leading to less GLP-1 release. In the human arm of the study, active GLP-1 concentrations fell significantly within four weeks  of atorvastatin therapy. Cell+1 Follow-up reviews summarize the idea this way: by shifting gut bacteria and bile acids, statins may unintentionally dial down your own GLP-1 signal—potentially nudging insulin resistance in the wrong direction, especially in those already at risk. Taylor & Francis Online That is not the last word (one paper never is), but it’s a credible biologic pathway linking statins → bile acids/microbiome → GLP-1 → insulin resistance. Do statins actually raise diabetes risk? Insulin resistance may be worsened by statin medications Short answer: yes, modestly —and the risk rises with higher-intensity dosing and in people already on the cusp of diabetes. An individual-participant meta-analysis of randomized trials (the most rigorous way to look) confirmed that statins increase the risk of new-onset diabetes , and clarified when and in whom it occurs. The Lancet+1 Mechanistic and clinical studies show increased insulin resistance  during statin therapy; for example, high-intensity atorvastatin over 10 weeks increased insulin resistance in non-diabetic adults. AHA Journals+1 Observational and trial meta-analyses consistently estimate a ~9–13% average increase  in diabetes risk across statins, with higher risks at intensive doses  (e.g., atorvastatin 80 mg), and particularly in those with pre-diabetes. nmcd-journal.com +1 A large cohort from Finland (METSIM) reported a higher, dose-responsive signal: 46% increased diabetes risk , tied to both decreased insulin sensitivity and insulin secretion. This is an outlier on the high end, but the design was careful and the pattern biologically plausible. PubMed+1 How might that tie back to GLP-1? The 2024 study suggests one pathway: if statins lower active GLP-1, the body’s post-meal insulin response and satiety signaling could be blunted, tending toward higher glucose and weight—especially in those with pre-existing insulin resistance. Cell What if I already have pre-diabetes? Pre-diabetes is a tipping-point condition. In several analyses, statin-associated dysglycemia is most evident in people who started close to that metabolic edge . High-intensity statins show the largest signal, and the effect appears dose-dependent. That’s not a reason to ignore your LDL or stop therapy abruptly; it is  a reason to individualize choices, intensify lifestyle therapy, and monitor glucose and A1c more closely. ScienceDirect+1 In short, know the risk-benefit analysis. Statins need not be given to everybody. Often, it seems, they are prescribed to everybody, as we have so frequently been told, 'The lower the cholesterol, the better.' From an observational standpoint, as well as a personal experiential standpoint, is entirely wrong. What about memory and dementia? Here the evidence is mixed  and, importantly, not  aligned with a clear harm signal: The FDA added labeling in 2012 noting rare, generally reversible  reports of memory loss or confusion with statins; they also noted small increases in blood sugar. This is real-world pharmacovigilance—signals to watch, not proof of ongoing injury. U.S. Food and Drug Administration+1 Randomized evidence to date has not shown prevention of dementia  by starting statins late in life; a Cochrane review concluded there was “good evidence” that statins do not  prevent cognitive decline or dementia in that context. Cochrane Library+1 Large observational syntheses are heterogeneous: some show neutral  effects; others suggest protective associations  (lower dementia risk among statin users). Observational results can be confounded (healthier users, better vascular care, etc.), so they don’t settle causality. Oxford Academic+1 Diabetes and Statins may contribute to Alzheimer's disease How do we square this with GLP-1? Chronically higher glucose and insulin resistance are linked to worse brain outcomes over time. If statins in some people  nudge glucose up (possibly via lower GLP-1), that metabolic effect could, indirectly, be unfavorable for the brain. But head-to-head evidence that statins cause  dementia is lacking, and several analyses point the other way. The most sensible stance: treat the vascular risk we know statins improve, while actively protecting metabolic and cognitive health with monitoring and targeted add-ons when needed.   The Lancet+1 Practical counseling: how we minimize downside while keeping upside Stratify your baseline risk. If your 10-year ASCVD risk is high, the cardiovascular benefits of statins are substantial. If your risk is moderate and you also have pre-diabetes, we weigh options more carefully (dose, molecule, or alternatives such as ezetimibe or bempedoic acid). Evidence of a small diabetes signal should be framed against the larger  heart-attack/stroke risk reduction in higher-risk patients. The Lancet Choose dose and molecule deliberately. Higher-intensity regimens carry a larger glycemic signal. Discuss whether a moderate-intensity statin  plus ezetimibe  (or bempedoic acid ) can reach LDL goals with less metabolic friction. nmcd-journal.com Track glucose proactively. Check fasting glucose, A1c, and—in those on the cusp—consider occasional post-meal  checks or a short CGM  trial to see what meals and medicines do in real life. Adjust diet (fiber, protein in early meals), activity (walks after meals), and timing. ScienceDirect Reinforce GLP-1–friendly habits. Protein with breakfast, viscous fibers (oats, legumes), fermented foods, and resistance training can all improve incretin tone and insulin sensitivity. If weight, appetite, or post-meal spikes worsen after starting a statin, bring this up—don’t white-knuckle it. Pharmacologic add-ons if needed. In people who develop hyperglycemia on statins—or who begin with pre-diabetes—consider therapies that enhance GLP-1 signaling  (GLP-1 receptor agonists, DPP-4 inhibitors) or improve insulin sensitivity (metformin) while continuing evidence-based lipid lowering. Drug–drug interactions with GLP-1 RAs are generally minor (slower gastric emptying can lower peak levels of some oral drugs), and the benefits for cardiometabolic risk are well established. SpringerLink+1 Cognition: monitor, don’t panic. If you notice new brain-fog or short-term memory issues after a statin starts or a dose increases, tell your clinician. Many cases are reversible  with dose adjustment or a switch in agent. Meanwhile, control of blood pressure, sleep apnea, glucose, exercise, and social/cognitive engagement are the heavy hitters for brain protection. U.S. Food and Drug Administration Bottom line for patients Statins may save lives,  by preventing heart attacks and strokes. A growing body of evidence indicates they can nudge glucose upward  and increase diabetes risk , particularly at higher doses and in those with pre-diabetes. A mechanistic link —reduced active  GLP-1 via microbiome/bile-acid changes—has now been demonstrated in humans. This, on the other hand, may cost lives. Cell Cognitive effects remain uncommon and typically reversible  when they occur; large randomized data do not  show dementia prevention from initiating statins late in life, and observational data on dementia risk are mixed . Cochrane Library+1 The best approach isn’t “statins good” or “statins bad.” It’s statins plus metabolic vigilance : choose the right intensity, monitor glucose, support GLP-1 biology with lifestyle (and, when appropriate, medication), and keep the heart-brain-metabolism picture in view. There is a time and a place for statin medications, but using them without better consideration of the populations at risk, will result in increased incidence of diabetes, obesity and dementia. Focus diagnosis and therapeutics on the inflammatory markers, as atherosclerosis starts as intravascular inflammation. Reduce inflammation through a better understanding of the factors that lead to intravascular inflammation, and intervene according to the chemistry that is required. Reduce the cholesterol value using natural and/or dietary approaches first. Statins have a bad public reputation, for no other reason than they make a significant number of persons 'feel bad,' as they are taken. References (15) She J , et al. Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner.   Cell Metab.  2024;36(2):408-421.e5. doi:10.1016/j.cmet.2023.12.027. [PubMed/Abstract] PubMed She J , et al. A gut feeling of statin: How gut microbiota modulate the therapeutic and side effects of statins.   Gut Microbes.  2024;16(1):e2291678. [Article] Taylor & Francis Online Cholesterol Treatment Trialists’ Collaboration  (Reith C, et al.). Effects of statin therapy on diagnoses of new-onset diabetes: individual participant data meta-analysis.   Lancet Diabetes Endocrinol.  2024;12(6):xxx-xxx. [Article/Abstract] The Lancet+1 Abbasi F , et al. Statins are associated with increased insulin resistance and insulin secretion in adults without diabetes.   Arterioscler Thromb Vasc Biol.  2021;41(11):e443-e455. [Article] AHA Journals Laakso M.   Statins and risk of type 2 diabetes: mechanism and clinical implications.   Front Endocrinol.  2023;14:1239335. [PMC] PMC Alvarez-Jimenez L , et al. Effects of statin therapy on glycemic control and insulin resistance: meta-analysis.   Pharmacol Res.  2023;190:106695. [Abstract] ScienceDirect Cederberg H , et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: METSIM cohort.   Diabetologia.  2015;58:1109-1117. [PubMed] PubMed Crandall JP , et al. Statin use and risk of developing diabetes: Women’s Health Initiative.   J Gen Intern Med.  2017;32(7):746-753. [PMC] PMC Casula M , et al. Statin use and risk of new-onset diabetes: meta-analysis of observational studies.   Nutr Metab Cardiovasc Dis.  2017;27(5):396-406. [Article] nmcd-journal.com Navarese EP , et al. Impact of different statin types/doses on new-onset diabetes: meta-analysis.   Am J Cardiol.  2013;111(8):1123-1130. [Abstract] ajconline.org Barkas F , et al. High-intensity statin therapy and incident diabetes—greater risk in prediabetes.   J Clin Lipidol.  2016;10(4):e-pub ahead of print. [Abstract] ScienceDirect Dabhi KN , et al. Assessing the link between statins and insulin intolerance: systematic review.   Cureus.  2023;15(6):e40112. [PMC] PMC U.S. FDA.   Drug Safety Communication: Safety label changes for statins (cognition and blood glucose).  2012. [FDA page] U.S. Food and Drug Administration McGuinness B , et al. Statins for the prevention of dementia.   Cochrane Database Syst Rev.  2016;CD003160. [Abstract] Cochrane Library Olmastroni E , et al. Statin use and risk of dementia or Alzheimer’s disease: meta-analysis of observational studies.   Eur J Prev Cardiol.  2022;29(5):804-814. [Article] Oxford Academic A final word If you’re on a statin (or considering one) and you also have pre-diabetes, diabetes, weight gain, or cognitive concerns, the right move is not  to stop therapy on your own. It’s to personalize  the plan: the right LDL goal, the right intensity, early glucose monitoring, GLP-1–supportive lifestyle (and medications if needed), and open communication about symptoms. That balanced strategy preserves the heart-protection statins offer while addressing the metabolic side of the ledger with equal seriousness. Subscribe to our Blog   Dr Klein's Facebook Page https://www.facebook.com/stagesoflifemedicalinstitute David S. Klein, MD FACA FACPM David S. Klein, MD, FACA, FACPM 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com David S. Klein, MD Functional Medicine Physician